Status:
UNKNOWN
Thrombin Generation Assay to Assess Thrombotic Risk in Nephrotic Patients
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Nephrotic Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
The thromboembolic risk is increased during the nephrotic syndrome (NS) with an incidence of deep vein thrombosis 15%, pulmonary embolism of 10-30% and renal vein thrombosis of 25-37%. There is a hemo...
Detailed Description
Thrombin generation test will be performed prospectively in nephrotic patients with various diseases (Minimal Change Disease (MCD), Malignant Nephrosclerosis (MN), Focal Segmental GlomeruloSclerosis (...
Eligibility Criteria
Inclusion
- Nephrotic syndrome
- Known cause of nephrotic syndrome (renal biopsy and/or positive anti-PLA2R)
Exclusion
- \- Active anticoagulation treatment before TGT
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2024
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT05301829
Start Date
April 1 2022
End Date
March 31 2024
Last Update
March 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de Néphrologie et Dialyses, Hôpital Tenon
Paris, France